Oxford Pharm Gp Share Discussion Threads

[burbelly] 26/9/2013 08:30

Could this not be a younger version?

mean while we just keep going up

[timbo003] 26/9/2013 08:29

OXP shareholders should take a look at Pozen




It is a company has actually successfully developed products which are currently on the market, it has a promising development pipeline, no debt, circa £50M in the bank, cash flow positive, a forward p/e of around 14. Yet it is only capitalised at around £100M

Compare and contrast with OXP and decide which looks better value.

[timbo003] 25/9/2013 18:11

Burbelly....LOL :)

[burbelly] 25/9/2013 18:06

Think that 250k late buyer @4.2 obviously smoking some good stuff too

[timbo003] 25/9/2013 17:58

Thanks doodlebug

Pozen are a neat little company with a decent portfolio of products, both approved and in development. However, the Pozen aspirin/omeprazol (PA32540) development is not really relevant to OXP.

* PA32540 is a combination product, not a single active.

* PA32540 reduces GI side effects by two mechanism, reduction in acid secretion in the stomach (omeprazole) and enteric coating.

* The second active, omeprazole is a proton pump inhibitor, it is indicated for prevention of GU ulcers.

* PA32540 is for secondary prevention of cardiovascular disease, not for analgesia.

* OXP001 (OXP's "safer" ibuprofen development) does not contain a proton pump inhibitor, nor does it involve an enteric coat.

* OXP001 uses ibuprofen, the incidence of serious GI side effects is much lower for ibuprofen than for aspirin, therefore it will be much more difficult to show any significant reduction in GI side effects with improved ibuprofen formulations, than with improved aspirin formulations.

* PA32540 had to lose its fast acting claims (because it was not bioequivalent. Although this has little relevance to aspirin for the prevention of secondary cardiovascular disease, if it were being marketed as an analgesic, it would be a show stopper.

* If OXP001 were not bioequivalent to standard ibuprofen with respect to speed of absorption, it would have to go in the SPC and it will lose speed claims (a disaster for an analgesic).

I think the N+1 Singer analyst must be smoking some good stuff. Can I try some please?

[doodlebug4] 25/9/2013 15:56

Thanks go to dreamcatcher on another bulletin board for that Burbelly.

[burbelly] 25/9/2013 15:44

Nice again, well found bug

[doodlebug4] 25/9/2013 15:36

Oxford Pharma could become major player in re-formulation market, says N+1 Singer
By Giles Gwinnett September 25 2013, 8:33am The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena BerryThe firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry

Broker N+1 Singer is "extremely upbeat" about the prospects for Oxford Pharmascience (LON:OXP) as it transforms into a drug re-development company.

Following a "solid" set of interims last week, the broker has lifted its intrinsic value for the firm by 26% to 11.6 pence a share, from 9.2 pence previously.

Shares are currently changing hands at 3.95p each.

The firm has shifted focus to developing products for the NSAID (non-steriod anti-inflammatory drug) and statin markets and clinical trials in both programmes are expected to begin next year, highlighted N+1 analyst Sheena Berry.

It will re-develop existing oral drugs to make them better and easier to take instead of the company's previous emphasis on its technology platforms.

Speaking to Proactive last week, chief executive Nigel Theobald pointed to the "massive deals" being done in the sector and singled out Sanofi's recent deal with Oxford Pharma's US peer, Pozen.

The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.

Analyst Berry noted that the Pozen and Sanofi-Aventis deal creates "a precedent" in this space, adding that Oxford has the ability "to take products to marketing authorisation itself, with the flexibility to consider and potentially establish partnerships in the interim".

"It is likely that the group will licence products on a market by market basis with the possibility of it entering certain markets on its own resources," she said.

"The group's ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market," she said.

Oxford Pharma's recent interim results revealed it is well funded with £6.65mln in cash at the period-end.

The stock, meanwhile, has been a top performer as it has undergone its transformation under CEO Theobald and the team as it has advanced 155% in the past year.

However Singer's price target points to further significant upside. "In our view, the group has a substantial opportunity to become a major player in the re-formulation market," concluded Berry.

"Our valuation is based on risk adjusted ten-year net present value analyses of the group's expected income streams. We are buoyant about the prospects that the group is capable of delivering."

[burbelly] 18/9/2013 23:28

Excellent news

[timbo003] 18/9/2013 22:43

The sales from the calcium product do seem to be going in the right direction and they get a fairly decent margin on it too (gross profit of £180K on sales of £500K). It's a pity (for shareholders) that they don't just try to concentrate on growing that part of the business, instead of pouring £millions into these long shots (OXPzero and SafeStat), which have little chance of success.

There is a link to a new video interview with the CEO on the web site, it sounds to me as if there will be another fund raising in the next 12 - 18 months:


Presumably they are anticipating doing a fund raise after the proof of concept (POC) studies which according to the slides on the video are due to complete towards the end of next year. I hope for shareholders sake, that the POC studies are not just PK studies (which in my view would not be POC, but a complete fudge around the issue on whether the two concepts have legs). They should set the primary objectives to look for real beneficial changes in pharmacodynamic (PD) effects rather than merely do further PK studies, which would prove very little IMO.

Another question I have, is why are they proposing testing two statins simultaneously, why not test them one at a time? If one works they should both work and if one fails they should both fail.

[doodlebug4] 18/9/2013 16:19

Oxford Pharmascience shares up as revenues jump by half
By Jamie Nimmo September 18 2013, 3:27pm Oxford Pharma is now focused on being on a drug re-development companyOxford Pharma is now focused on being on a drug re-development company


Shares in AIM-listed Oxford Pharmascience (LON:OXP) received a shot in the arm on Wednesday when it revealed first-half revenues jumped 47% as it refocused the business on drug re-development.

The £501,000 generated in the six months to June 30 outstripped the total revenues from 2012, while the loss before tax increased slightly to £585,000, from £399,000 the year before.

It came as the company opted to redevelop existing oral drugs to make them better and easier to take instead of the previous emphasis on its technology platforms.

Shares rose 4.2% to 3.83p each on the news.

"The future is incredibly exciting and existing business growth shows a glimpse of what the group can do once its products reach market," chairman David Norwood said in a statement.

"This is just the start of what the future has to offer for Oxford Pharmascience and I am delighted at the speed of transition the group has shown in the first 6 months of 2013."

The shift in focus will see the company work predominantly on non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and statins, used to reduce cholesterol, which have combined global sales of $24bn and are dominated by off-patent drugs.

NSAIDs and statins have serious side effects, which limit their use. Oxford Pharma plans to reformulate these drugs with reduced side effects.

The technologies it has been developing up to this point will be used to develop improved formulations of existing pain relief drugs and cardiovascular treatments.

Chief executive Nigel Theobald told Proactive Investors that redeveloping existing drugs is a quicker and cheaper way of getting a drug to market.

"Because they're already proven to be safe and effective, bringing new versions of these drugs to market will take on average just two to three years at around £5mln a drug," he explained.

"If we were developing a totally new drug in these areas, that would take over 10 years and cost over £1bn.

"For a fraction of the investment, you can see huge returns by redeveloping these existing drugs."

Theobald added: "We've already established our technology platforms and seen the potential. So we're now redeveloping existing drugs ourselves to make them better and easier to take."

He said the second half of the year has started well, with Brazilian partner Aché launching a second version of the company's calcium chew.

Theobald also highlighted the "massive deals" being done in the sector, pointing in particular to Sanofi's recent deal with Oxford Pharma's US peer Pozen.

The French pharma giant agreed to pay Pozen US$35mln earlier this month for a combination aspirin and omeprazole pill that avoids common side effects.

Oxford Pharma ended the six months with £6.65mln in cash, compared with just £639,000 in the same period last year.

N+1 Singer hailed a "solid" set of results from the company, highlighting the "impressive growth" shown in the numbers.

"The group's ambition in both areas has potentially massive implications going forward and we continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market," said analyst Sheena Berry.

[gnnmartin] 18/9/2013 15:36

A very encouraging interim statement. To quote from the chairman's statement:
"The future is incredibly exciting and existing business growth shows a glimpse of what the Group can do once its products reach market. Our calcium product continues to grow from strength to strength. Group sales for the first half of 2013 were £501,000, 47% higher than the same period last year and 7.5% higher than the whole of 2012. Strong growth in sales is expected to continue in the second half of 2013."
Nigel Martin

[master rsi] 06/9/2013 12:45

Shares bouncing from support it seems

[timbo003] 06/8/2013 12:45

Doodlebug, I doubt if she would correspond with me, she works for the company's Nomad after all, so she needs to tow the line to a certain extent. Besides which, I have nothing to lose if and when it all goes pear shaped, whereas, shareholders do.

[doodlebug4] 06/8/2013 12:39

You go ahead timbo, you are the one who is expressing the reservations!

[timbo003] 06/8/2013 12:36

If I were a shareholder in OXP, I would get in touch with the N+1 Singer analyst who covers OXP and put some of the reservations that I have expressed on this thread to her and see how she responds. It could be that I am reading it all the wrong way, but I very much doubt it.

Her contact details are as follows:

Sheena Berry:
020 7496 3078
[e-mail]

[doodlebug4] 05/8/2013 16:49

Speciality pharma group Oxford Pharmascience's (LON:OXP) establishment of a Scientific Advisory Board and the appointment of Professor Bill Dawson indicate the progression of the group's existing development plan remains on track, said house broker N+1 Singer.

"Momentum of moving towards human proof of concept trials in both the NSAIDs and Statin programmes continues to build. We re-iterate our upbeat view and believe the group is capable of becoming a major player in the reformulation market. We retain our 9.2p intrinsic value per share." Shares were 3.7p today.


from www.directorstalk

[timbo003] 04/8/2013 20:29

LOL, I don't think Marcelo would not want me on the panel!

A few observations:

* Why will the scientific advisory board have non-scientist members?
* How can the scientific advisory board be independent if Marcelo is a member?
* Why is it being chaired by an Octogenarian?
* Why not get someone who is still active in academia with a reputation to build?
* Bill Dawson seems to have collected numerous non-exec roles since retiring from Lilly, so I assume he knows how to play the game and to say the right things to keep his paymasters happy.

[burbelly] 02/8/2013 14:18

they should ask Timbo to join the board

[doodlebug4] 02/8/2013 14:04

RNS
RNS Number : 8525K
Oxford Pharmascience Group PLC
02 August 2013



Oxford Pharmascience Group plc



("Oxford Pharmascience" or "the Company")





Oxford Pharmascience establishes Scientific Advisory Board





Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces establishment of a scientific advisory board to support its medicines reformulation programme.



The Scientific Advisory Board shall consist of the Chief Technology Officer and independent world class experts, providing a broad range of expertise in both basic and clinical sciences, as well as technologies. The Scientific Advisory Board will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the Company's business.



As a first step, the company is appointing Professor Bill Dawson to serve on the scientific advisory board. Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.



Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes. Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D programmes is invaluable as we enter a new stage as a company. We plan to continue building the Scientific Advisory Board with further appointments in the coming months."

[doodlebug4] 29/7/2013 22:00

SMALL CAPS SHARE TIPS: Uni tie-up and statins breakthrough gives Oxford Pharmascience a shot in the arm

By John Harrington, Proactive Investors

PUBLISHED: 17:43, 29 July 2013 | UPDATED: 18:10, 29 July 2013


Shares in Oxford Pharmascience continue to perform well as investors sharpen their focus on its innovative work with University College London.

Investors appear keen to back the company which has just inked a new deal to extend and deepen its collaboration with UCL and the university's well-regarded Phloral technology.

The idea is that together they will apply innovative drug delivery technology, which will allow more effective dosing, and hopefully reduce side-effects as a result. The partners have already had success with this kind of work on statins, a cholesterol busting drug.

One of the major problems with statins is that many users suffer unpleasant side effects such as inflammation and muscle damage.

A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient's cholesterol level.


However, Oxford Pharma has reformulated two of the most widely used generic statins, Atorvastatin and Simvastatin, which will allow them to be delivered to the colon where they are more effectively absorbed into the liver.

The new agreement, signed last week, gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the UCL's know-how.

The new deal will see Oxford Pharma get first pick of a different batch of compounds.


.
'It's the same technology that we're licensing,' Nigel Theobald, Oxford Pharma's chief executive, explained to Proactive Investors.

Oxford Pharma has until March next year to investigate the potential for the 53 compounds and it can then spend another year assessing those with the best commercial and clinical potential.

Speaking about the compounds, Theobald said: 'Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.'

Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangements should these programmes lead to commercial products, but it is likely that any deal would be similar to the terms to other existing terms for statins.


'We're just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They're delighted, and we're delighted. It's a good win-win,' Theobald said.

Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.

'Having already told the world how to do it, we want to make sure that people don't try to get in ahead of us.'

It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.

'All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,' Theobald revealed.

'Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.

'There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.'

Theobald was keen to emphasise that last point about the new deal not being a distraction to the company's existing work programmes.

'The redevelopment work that we do will be quick and it will be relatively cheap,' Theobald said.

[burbelly] 25/7/2013 22:16

another 16m went through after the bell

[multibagger] 25/7/2013 07:19

TIDMOXP

RNS Number : 0548K

Oxford Pharmascience Group PLC

25 July 2013

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience signs option with UCL to explore further compounds.

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that it has signed an option agreement with UCL ("University College London" to investigate 53 further compounds that it could potentially commercialise using UCL's Phloral(TM) technology.

Following closely working with UCL on the Company's program for Atorvastatin and Simvastatin, it has identified a further 53 compounds which might benefit from reformulation using Phloral(TM) to reduce their associated side effects.

The Company has agreed an option period until March 2014 to investigate the potential for these compounds with a further option period for another year to explore more thoroughly those compounds that it will identify to have the greatest commercial and clinical potential.

Nigel Theobald Chief Executive of Oxford Pharmascience commented

"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programs for NSAIDs (non steroidal anti inflammatory drugs) and Statins.

There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programs.

We are committed to building a strong portfolio of reformulated drugs to deliver the high returns of new drug development but without the high risks."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive [phone]

N+1 Singer

Shaun Dobson/Jenny Wyllie [phone]

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

About UCL (University College London)

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 24,000 students from almost 140 countries, and more than 9,500 employees. Our annual income is over GBP800 million.

www.ucl.ac.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END